| Supplier |
CD Formulation |
| Product # |
PE-0509 |
| Pricing |
, Inquire for price
|
| product1 |
Pharmaceutical Excipients
|
| Safety |
Bolaclin potassium and other Bolaclin resins can be used in oral pharmaceutical preparations and are generally considered non-toxic and non-irritating. But excessive consumption of Polaclin can disrupt the body's electrolyte balance.
|
| Incompatibilities |
Incompatibility with strong oxidants, amines, especially tertiary amines, and certain substances that interact with Polaclin resins.
|
| CAS Number |
5060-22-16
|
| Category |
Carrier Excipients
|
| UNII |
RCZ785HI7S
|
| Grade |
Pharmceutical Excipients
|
| Administration route |
Oral, percutaneous
|
| Dosage Form |
Tablets, chrew, orally distegrating
|
| Stability and Storage Conditions |
Polaclin potassium and other Polaclin resins are stable to light, air and heat at their highest operating temperatures. Excessive heating causes thermal decomposition of the resin, producing one or more oxides of carbon, nitrogen, sulfur and/or amine. Polaclin resin should be sealed and stored in a cool and dry place.
|
| Commonly used amount and the maximum amount |
Maximum dosage of marketed tablets: 3.00mg; Maximum dose of transdermal administration: 1.10mg; Maximum dose of oral chewing: 8.1mg/g
|
| Source and Preparation |
Polaclin resin (Amberlite IRP-65) is a copolymerization of methacrylic acid and divinylbenzene (DVB).
|